Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

KPTIKaryopharm Therapeutics IncFinished

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Relapsed/Refractory Multiple Myeloma (RRMM) · Metastatic Colorectal Cancer (mCRC) · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Higher-Risk Myelodysplastic Syndrome (HR-MDS) · Acute Myeloid Leukemia (AML) · Newly Diagnosed Intermediate/High-Risk MDS

11Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Aug 2024, none posted yet

    Counts until it's fixed

    +10

  • 6 insiders sold shares within a month

    Since May 14, 2026 · was worth 10, fading over time

    +1.3
Worry score11

Score over time

Stage
Phase 1/2
Patients
277 (planned)
Started
Jan 2016
Main results expected
Aug 31, 2024
Fully finished
Dec 23, 2024
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    Measured over: Approximately 4 weeks

  • Part A1, A2, B, C, D, E, F: Overall Response Rate (ORR)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Duration of Response (DOR)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Progression-free Survival (PFS)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Overall Survival (OS)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Clinical Benefit Rate (CBR)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Duration of Clinical Benefit Rate (CBR)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Disease Control Rate (DCR)

    Measured over: Approximately 8 years

  • Part A1, A2, B, C, D, E, F: Duration of DCR

    Measured over: Approximately 8 years

  • Part F Phase 2: ORR

    Measured over: Approximately 8 years

  • Part G: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    Measured over: Approximately 8 years

  • Part H: 2- Year Progression-free Survival (PFS)

    Measured over: Approximately Up to 2 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2024-08-31, no fading
  • insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT02649790 · record last updated 2025-03-19 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT02649790) ↗